By Vinita Navadgi | October 3, 2025| Drug Discovery and Development
Three days before the ACIP’s meeting last week, Robert F. Kennedy Jr. appointed five new members to the ACIP, a process that usually takes months. The panel now has a total of 12 members. The new members will “bring diverse expertise that strengthens the committee and ensures it fulfills its mission with transparency, independence, and… The post RFK appointed five new members to ACIP appeared first on Drug Discovery and Development.| Drug Discovery and Development
Last Friday, the ACIP voted to recommend COVID vaccination “based on individual-based decision-making” for adults 65 and older. For individuals 6 months to 64 years old, the vaccine is recommended based on individual decision, “with an emphasis that the risk-benefit of vaccination is more favorable for individuals who are at an increased risk for severe… The post ACIP recommends COVID vaccine based on “individual decision making” appeared first on Drug Discovery and Development.| Drug Discovery and Development
The ACIP met this week to vote on recommendations for the MMRV, Hepatitis B and COVID vaccines. On Thursday, they voted to recommend separate MMR and varicella vaccines for children under four, instead of the combination MMRV vaccine. On Friday, they voted to table the Hepatitis B decision for another meeting. Also on Friday, the… The post ACIP voted to stop recommending MMRV vaccine for young children appeared first on Drug Discovery and Development.| Drug Discovery and Development
AUTOMA+ 2025 is the fifth edition of the Pharmaceutical Automation and Digitalisation Congress, a closed-door, pre-registered meeting expected to draw 300+ participants in Vösendorf, Austria (Nov. 24–25). The 2025 program focuses on implementations in automation, data integrity/validation (CSA/CSV), AI in operations, and integration across MES/LIMS/ERP/QMS. Launched virtually in 2021 and convened in Zurich in 2024,… The post AUTOMA+ 2025 to cover pharma automation and digitalization tren...| Drug Discovery and Development
Sai Life Sciences, a Hyderabad-based contract research, development, and manufacturing organization (CRDMO) has opened Unit VI, a dedicated veterinary-API facility in Bidar, India, adjacent to the company’s flagship API site. The company positions the site to supply animal-health sponsors and contract customers, citing rising demand for veterinary medicines and the need for dedicated manufacturing capacity… The post Sai adds dedicated veterinary-API capacity in India as part of a broader ...| Drug Discovery and Development
Despite some vocal attacks against vaccines, a poll conducted by Republican pollsters — including Donald Trump’s chief pollster — shows “that there is broad unity across party lines supporting vaccines such as measles (MMR), shingles, tetanus, diphtheria and pertussis (TDAP), and Hepatitis B.” NBC News reported that the poll results were made known to Republican… The post Bipartisan support for vaccines could be a balm for beleaguered vaccine companies appeared first on Drug Disco...| Drug Discovery and Development
It turns out that AI really is doing the work. At least a growing chunk of it. Artificial intelligence is spreading through the global workforce like wildfire, dwarfing the adoption pace of the internet, with a new Anthropic report citing Gallup research that 40% of U.S. employees now use AI at work. While the field… The post As the pharma industry grapples with a talent shortfall, AI makes inroads in drug-safety workflows appeared first on Drug Discovery and Development.| Drug Discovery and Development
Women’s Health Access Matters (WHAM) has opened nominations for its 2025 Edge Awards, providing $25,000 grants to early-career investigators studying sex-based differences in health outcomes. The awards target research in autoimmune diseases, brain health, cancer and heart health, conditions that often affect women differently than men. For the first time, WHAM is also accepting proposals… The post WHAM launches 2025 Edge Awards to support early-career researchers in women’s health appe...| Drug Discovery and Development
In the dynamic world of facility planning and expansion, the initial pre-stages are critical to a project’s success. In advance of diving into feasibility studies, project teams aim to engage in thorough pre-planning discussions to establish clear goals, address logistical challenges, and align design requirements with business needs. Pre-planning is crucial for the success of… The post Laying the groundwork: How pre-planning drives successful facility expansions appeared first on Drug Di...| Drug Discovery and Development
Eli Lilly launched “TuneLab,” an AI/ML platform that gives selected biotechs access to drug-discovery models trained on years of Lilly research data. Initial public partners include Circle Pharma and insitro. Lilly says the first release reflects more than $1B worth of internal data investment. Lilly says biotechs run its models locally on their own infrastructure… The post Lilly launches TuneLab, sharing AI drug-discovery models with biotechs appeared first on Drug Discovery and Develo...| Drug Discovery and Development
Only 7.1% of U.S. adults with cancer enroll in treatment trials (JCO, 2024), a bottleneck that slows drug development and limits access to targeted therapies. Proscia, a Philadelphia-based digital pathology company, aims to address that dynamic with its new tool, Aperture, which uses AI to flag potential candidates right at the point of diagnosis by… The post Proscia launches ‘Aperture’ AI platform to accelerate clinical trial recruitment at point of diagnosis appeared first on Drug Dis...| Drug Discovery and Development
Novo Nordisk, the manufacturer of Ozempic, announced a plan to reduce its global workforce by approximately 9,000 positions today. Around 5,000 positions are expected to be cut in Denmark. This will reduce the company’s workforce from its current 78,400 positions to approximately 69,400. The company’s stock has fallen about 58% over the past year as… The post Novo Nordisk to cut 9,000 jobs globally to compete in GLP-1 market appeared first on Drug Discovery and Development.| Drug Discovery and Development
On Friday, Kevenue, the maker of Tylenol, saw its stocks drop more than 10% after the Wall Street Journal reported that Health and Human Services Secretary Robert F. Kennedy plans to release a federal report connecting prenatal use of Tylenol to autism. As Kennedy and his appointed vaccine panel continue to erode vaccine recommendations, many… The post Vaccine makers’ stocks continue to spiral as the segment faces fresh pressures appeared first on Drug Discovery and Development.| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Stay updated with drug discovery trends on drugdiscoverytrends.com. Dive into pharma and biotech insights, from AI to neurological disease.| Drug Discovery and Development
By Brian Buntz | June 23, 2025| Drug Discovery and Development
In 2024, Merck's Keytruda continued to dominate with $29.5 billion in sales, growing 18% over 2023's $25 billion in sales.| Drug Discovery and Development
By Julia Rock-Torcivia | June 9, 2025| Drug Discovery and Development
By Julia Rock-Torcivia | June 9, 2025| Drug Discovery and Development
By Julia Rock-Torcivia | June 9, 2025| Drug Discovery and Development
By Brian Buntz | June 25, 2025| Drug Discovery and Development
By Dr. Qigan Cheng | August 18, 2025| Drug Discovery and Development
Dr. Joseph A. Ladapo, the Florida surgeon general, announced at an event on Wednesday that the Department of Health, working with the governor, would “end all vaccine mandates in Florida law.” He also compared vaccine mandates to slavery. “Your body is a gift from God. What you put into your body is because of your… The post Florida could become the first state to remove vaccine mandates for school appeared first on Drug Discovery and Development.| Drug Discovery and Development
Modern medicine and vaccines have saved millions of lives, but this comes with an environmental cost. A 2019 report by Health Care Without Harm found that the broader health care sector contributes 4.4% of the global total net emissions. This is equivalent to two gigatons of carbon dioxide, the annual greenhouse gas (GHG) emissions from… The post Pharma’s environmental impact and how companies are reducing their footprints appeared first on Drug Discovery and Development.| Drug Discovery and Development
Novartis has signed a global licensing agreement with Arrowhead Pharmaceuticals for the preclinical RNA interference (RNAi) therapy ARO-SNCA, targeting alpha-synuclein in Parkinson’s disease and related disorders. The deal, announced Tuesday and reported by Reuters, includes a $200 million upfront payment to Arrowhead, with up to $2 billion in potential milestones, plus tiered royalties (capped in… The post Novartis bets $200M upfront on Arrowhead’s Parkinson’s RNAi, total value up to...| Drug Discovery and Development
Biomarkers are strategic assets for biopharma companies, significantly improving the success rate of clinical trials1. Yet, discovering them often feels like navigating through a blizzard of unstructured information, searching for the one true signal that can guide the way. While laboratory automation has eased benchwork, the real storm rages in the data, obscuring access to… The post Finding signals in the storm: Automation in biomarker discovery appeared first on Drug Discovery and Deve...| Drug Discovery and Development
by Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator safety. Among the many variables that must be tightly controlled, pressure ranks high on the list. Overpressure or vacuum conditions can compromise not only equipment, but also batch sterility, production timelines, and… The post Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Desi...| Drug Discovery and Development
By Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last few decades — but are typically very costly. With patent expirations encompassing numerous notable oncology biologics, opportunities for oncology biosimilar development are abundant. Biosimilars, less expensive treatments made to closely emulate biologics with expired patents,… The post What sets oncology biosimilars apart: Anticipating key challenges in the dev...| Drug Discovery and Development
Pfizer Inc. and BioNTech SE announced today that the FDA has approved their COVID-19 vaccine for adults ages 65 and older and individuals from 5 to 64 years old who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. The approval comes amidst the development of a… The post Pfizer and BioNTech’s COVID vaccine approved for individuals at increased risk appeared first on Drug Discovery and Development.| Drug Discovery and Development
Healthcare is one of the largest sources of “big data,” accounting for upwards of 30% of all data produced globally.1 Early on, the potential benefits of this data for healthcare outcomes were immediately evident. As that promise has begun to materialize, with the advent of AI and machine learning, real signals of improvement in therapeutic… The post Early-phase study design considerations for long-term follow-up in vaccine clinical trials appeared first on Drug Discovery and Development.| Drug Discovery and Development
The U.S. Centers for Disease Control and Prevention chose Retsef Levi, a management and health analytics expert at MIT, to lead its COVID-19 immunization workgroup. Levi announced on X that he is “looking forward to working with colleagues… to pursue the truth through science and evidence-based approach.” Levi, one of the eight new ACIP members… The post ACIP’s COVID vaccine workgroup to be headed by vaccine skeptic Retsef Levi appeared first on Drug Discovery and Development.| Drug Discovery and Development
IQVIA experts explain how implementation science accelerates adoption of medical advances, improving evidence-based care and patient outcomes.| Drug Discovery and Development
By Ryan N. Phelan | April 28, 2025| Drug Discovery and Development
The one-drug-many-indications model has steadily grown in popularity since the early 2000s. But Irvine, California–headquartered Tarsus Pharmaceuticals is aiming to bring the model to XDEMVY (lotilaner), an antiparasitic drug that first won FDA-approval in dogs. After licensing lotilaner from Elanco, Tarsus won FDA approval for the drug, under the trade name XDEMVY, for the treatment… The post Q2 net sales reach $100M for Tarsus’ XDEMVY, a potential treatment for Lyme and malaria rooted...| Drug Discovery and Development
Bispecific antibodies are a rapidly advancing class of therapeutics, offering a new level of precision in treating diseases like cancer.| Drug Discovery and Development
Cedars-Sinai researchers boost ACE enzyme in brain immune cells, dramatically reducing Alzheimer's plaques and reversing cognitive decline in mice.| Drug Discovery and Development
Eli Lilly and Co. has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion, in a move that bolsters Lilly's push into gene editing for cardiovascular conditions and signals renewed confidence in the sector.| Drug Discovery and Development
Boltz-2, a new open-source model from MIT and Recursion available on GitHub, delivers FEP-class accuracy in about 18 seconds on a single GPU.| Drug Discovery and Development
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language… The post Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classifi...| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
By Brian Buntz | September 8, 2025| Drug Discovery and Development
By Vinita Navadgi | October 3, 2025| Drug Discovery and Development
Genmab, a Danish company focused on developing antibody therapies for patients with cancer, opened a new site in Plainsboro, NJ.| Drug Discovery and Development
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
Dupixent (dupilumab) has been approved by the FDA for the treatment of adult patients with bullous pemphigoid.| Drug Discovery and Development
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
By Will Torres, Maryam Youssef and Kasia Koczula | July 9, 2025| Drug Discovery and Development
By Julia Rock-Torcivia | September 22, 2025| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Cambridge-based biotechnology company Parallel Bio has closed a $21 million Series A funding round led by AIX Ventures.| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Sanofi and Regeneron have announced that the monoclonal antibody outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints in a phase 4 study focused on patients with chronic rhinosinusitis.| Drug Discovery and Development
The FDA has approved zoliflodacin for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older.| Drug Discovery and Development
The FDA has approved ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants and newborns.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
Labcorp rolls out new NGS panels, HRD testing, and a Leica-Proscia digital pathology platform to accelerate biomarker screening.| Drug Discovery and Development
From accelerating drug discovery and optimizing clinical trials to automating regulatory documentation and improving patient engagement, AI offers opportunities to improve efficiency, reduce costs, and bring therapies to market faster.| Drug Discovery and Development
The once pioneering DNA test company 23andMe is now a penny stock that has filed for bankruptcy. Its CEO Anne Wojcicki is also stepping down.| Drug Discovery and Development
They are highly effective at suppressing inflammation and the reducing the activity of the body’s immune system, providing rapid relief from associated symptoms.| Drug Discovery and Development
By Brian Buntz | February 19, 2025| Drug Discovery and Development
By Brian Buntz | April 30, 2025| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
AnaptysBio’s investigational drug rosnilimab has delivered promising Phase 2b trial results for moderate-to-severe rheumatoid arthritis.| Drug Discovery and Development
Capturing complete, consistent, and contextualized data is vital in AI/ML, especially within the biopharma industry.| Drug Discovery and Development
$1B women's health push and RNAi advances mark JPM 2025, with solid tumor therapies gaining momentum| Drug Discovery and Development
Novo Nordisk continues to face supply shortages for its Wegovy (semaglutide) pens, which are FDA approved for weight management.| Drug Discovery and Development